Introduction Androgen deprivation therapy (ADT) remains the mainstay of treatment for
metastatic prostate cancer (mPCa) but is associated with significant morbidities …

Background Androgen deprivation therapy (ADT) is the gold standard for metastatic prostate
cancer, which can be achieved either by surgical or medical castration. In this study, we …

Introduction Androgen deprivation therapy (ADT) is a well-established treatment for
metastatic hormone-sensitive prostate cancer (mHSPC). It includes either bilateral …

Background. Most patients with metastatic prostate cancer are endocrinologically treated
with LHRH agonist, but finally castration-refractory and hormone-refractory cancers occur …

Objective: Rapid control of the disease is essential in the management of patients with
critical and symptomatic metastatic prostate cancer. Pharmacological castration has become …

Objective To determine the attitudes and education regarding surgical castration in men
receiving androgen deprivation therapy (ADT) for metastatic prostate cancer (mCaP) …

Purpose: Surgical castration for metastatic prostate cancer is used less frequently than
medical castration yet costs less, requires less followup and may be associated with fewer …

Objective: Patients with metastatic prostate cancer who are initially treated by oral
antiandrogens and then have progressive disease may be offered surgical castration as a …

Purpose To define the efficacy of standard androgen deprivation therapy (ADT) in the
treatment of metastatic prostate cancer (PCa). Materials and methods Fifty patients with …

Objective: At the time of diagnosis, approximately 16.5% of prostate cancer patients are
metastatic. The main framework of metastatic prostate cancer treatment is androgen …